Kudo Masatoshi, Kurosaki Masayuki, Ikeda Masafumi, Aikata Hiroshi, Hiraoka Atsushi, Torimura Takuji, Sakamoto Naoya
Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University.
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital.
Hepatol Res. 2020 Sep;50(9):1004-1014. doi: 10.1111/hepr.13541. Epub 2020 Jul 20.
This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID-19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections.
由于冠状病毒病（COVID-19）大流行，肝细胞癌（HCC）的标准治疗面临压力。所需措施可能因地区和个别机构而异，这取决于大流行造成的压力程度（例如，感染COVID-19的住院患者数量以及包括个人防护装备和住院床位在内的资源可用性）。此外，模型显示，在日本有效疫苗和药物广泛可用之前（预计时间为2至3年），COVID-19的第二波和第三波疫情将会出现。鉴于COVID-19感染激增可能导致医疗系统即将崩溃的风险，本指南应为HCC管理的最佳实践提供良好参考。
